Pardon my ignorance in this area @ttppxx, you refer to "how the COBRA Reference Standard was constructed" in reation to "A positive 64Cu-SAR-bisPSMA scan shall be considered a False Positive if the Reference standard is Negative".
Which party constructs the Reference Standard for a trial? I assumed it was Clarity itself.
If so, wouldn't the decision to allocate a scan as False Positive if the Reference standard is Negative just be a matter of taking a conservative approach?
Doesn't this effectively render the trial almost useless. I suppose it tests whether the trialled product is as good, just not whether it's better?
Thanks, appreciate your contribution here
CU6 Price at posting:
$2.68 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)